Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma”

H. Sasaki, M. Zlatescu, R. Betensky, Loki Johnk, Andrea N. Cutone, J. Cairncross, David N. Louis
{"title":"Histopathological‐Molecular Genetic Correlations in Referral Pathologist‐Diagnosed Low‐Grade “Oligodendroglioma”","authors":"H. Sasaki, M. Zlatescu, R. Betensky, Loki Johnk, Andrea N. Cutone, J. Cairncross, David N. Louis","doi":"10.1093/JNEN/61.1.58","DOIUrl":null,"url":null,"abstract":"Allelic loss of chromosome 1p predicts increased chemosensitivity and better survival in oligodendroglial tumors. Clinical testing for 1p loss in oligodendroglial tumors at our hospital has allowed us to postulate that certain histological appearances are associated with 1p allelic status. Forty-four cases received for genetic testing were diagnosed by referring pathologists as pure low-grade oligodendroglioma. Central neuropathological review divided the series equally into 22 cases with classical oligodendroglioma histology and 22 with more astrocytic features. Molecular genetic analyses demonstrated 1p loss in 19 of 22 classic oligodendrogliomas (86%) and maintenance of both 1p alleles in 16 of 22 gliomas with astrocytic features (73%). No glial fibrillary acidic protein-positive cell type (gliofibrillary oligodendrocyte, minigemistocyte, cellular processes) was associated with 1p allelic status. Fourteen of the 44 cases were treated with chemotherapy at tumor progression: 3 “astrocytic” gliomas with 1p loss responded to PCV chemotherapy and 2 classic oligodendrogliomas that maintained both 1p alleles included a responder and a non-responder. These results suggest that histological appearance correctly predicts genotype in approximately 80% of low-grade gliomas, but that tumor genotype more closely predicts chemosensitivity. As a result, such objective molecular genetic analyses should be incorporated into patient management and into clinical trials of low-grade diffuse gliomas.","PeriodicalId":14858,"journal":{"name":"JNEN: Journal of Neuropathology & Experimental Neurology","volume":"24 1","pages":"58–63"},"PeriodicalIF":0.0000,"publicationDate":"2002-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"139","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNEN: Journal of Neuropathology & Experimental Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/JNEN/61.1.58","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 139

Abstract

Allelic loss of chromosome 1p predicts increased chemosensitivity and better survival in oligodendroglial tumors. Clinical testing for 1p loss in oligodendroglial tumors at our hospital has allowed us to postulate that certain histological appearances are associated with 1p allelic status. Forty-four cases received for genetic testing were diagnosed by referring pathologists as pure low-grade oligodendroglioma. Central neuropathological review divided the series equally into 22 cases with classical oligodendroglioma histology and 22 with more astrocytic features. Molecular genetic analyses demonstrated 1p loss in 19 of 22 classic oligodendrogliomas (86%) and maintenance of both 1p alleles in 16 of 22 gliomas with astrocytic features (73%). No glial fibrillary acidic protein-positive cell type (gliofibrillary oligodendrocyte, minigemistocyte, cellular processes) was associated with 1p allelic status. Fourteen of the 44 cases were treated with chemotherapy at tumor progression: 3 “astrocytic” gliomas with 1p loss responded to PCV chemotherapy and 2 classic oligodendrogliomas that maintained both 1p alleles included a responder and a non-responder. These results suggest that histological appearance correctly predicts genotype in approximately 80% of low-grade gliomas, but that tumor genotype more closely predicts chemosensitivity. As a result, such objective molecular genetic analyses should be incorporated into patient management and into clinical trials of low-grade diffuse gliomas.
转诊病理学诊断的低级别“少突胶质细胞瘤”的组织病理学-分子遗传学相关性
染色体1p的等位基因缺失预示着少突胶质肿瘤的化疗敏感性增加和生存率提高。在我院对少突胶质肿瘤中1p缺失的临床检测使我们能够假设某些组织学表现与1p等位基因状态有关。44例接受基因检测的病例经病理诊断为纯低级别少突胶质细胞瘤。中枢神经病理检查将该系列平均分为22例具有典型少突胶质细胞瘤组织学和22例具有更多星形细胞特征。分子遗传学分析显示22例典型少突胶质细胞瘤中有19例(86%)1p基因缺失,22例具有星形细胞特征的胶质瘤中有16例(73%)1p等位基因同时维持。胶质原纤维酸性蛋白阳性细胞类型(胶质原纤维少突胶质细胞、小细胞分裂细胞、细胞过程)与1p等位基因状态无关。44例患者中有14例在肿瘤进展时接受化疗:3例“星形细胞”胶质瘤对PCV化疗有反应,1p等位基因丢失,2例经典少突胶质胶质瘤维持1p等位基因,包括有反应和无反应。这些结果表明,组织学外观正确地预测了大约80%的低级别胶质瘤的基因型,但肿瘤基因型更接近于预测化疗敏感性。因此,这种客观的分子遗传学分析应纳入低级别弥漫性胶质瘤的患者管理和临床试验中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信